US2018155418A1PendingUtilityA1

Il-31 antibody compositions

66
Assignee: ZYMOGENETICS INCPriority: Jan 18, 2002Filed: Feb 10, 2017Published: Jun 7, 2018
Est. expiryJan 18, 2022(expired)· nominal 20-yr term from priority
Inventors:Cindy A. SprecherJoseph L. KuijperMaria M. DasovichFrancis J. GrantJane A. GrossAngela K. Hammond
A61P 43/00A61P 37/08A61P 37/02A61P 37/00A61P 7/00A61P 35/00A61P 29/00A61P 31/04A61P 19/02A61P 11/06A61P 11/00A61P 17/06A61P 1/04A61P 15/08A61P 1/02C07K 14/52A61K 38/00C07K 14/47A01K 2217/05C07K 2317/24C07K 16/24G01N 33/567C12N 15/63
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A composition comprising a monoclonal antibody and a pharmaceutically acceptable carrier, wherein the monoclonal antibody specifically binds a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2. 
     
     
         2 . The composition of  claim 1 , wherein the monoclonal antibody is human. 
     
     
         3 . The composition of  claim 1 , wherein the monoclonal antibody is humanized

Join the waitlist — get patent alerts

Track US2018155418A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.